Skip to content

Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management

Utilization of the Natural History of Medullary Thyroid Carcinoma to Inform Advanced Disease Management

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04216732
Enrollment
2030
Registered
2020-01-03
Start date
2020-01-10
Completion date
2026-09-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8

Brief summary

This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.

Detailed description

PRIMARY OBJECTIVES: I. To describe the natural history of medullary thyroid cancer (MTC) using a comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in our existing multi-institutional patient registry. Ia. To describe the demographic, clinical, pathologic, and genotypic variables associated with each phase of disease. Ib. To identify those variables which are predictors of progression to the most advanced phases of disease that require small molecule therapy, including commercially approved and experimental agents. II. To characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs). IIa. To describe clinical, psychosocial, economic, and physical well-being variables and the subsequent impact on quality of life associated with each phase of disease. IIb. To evaluate longitudinal changes in clinical, psychosocial, economic, and physical well-being variables between and within all phases of MTC, and the subsequent impact they have on quality of life. III. To evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial. OUTLINE: AIM I & II: Patients complete questionnaires over 10-40 minutes 2-4 times per year about health and how finances and quality of life effect experience with disease. AIM III: Patients complete a questionnaire over 2 minutes and undergo blood pressure measurements every day for up to 12 weeks. The questionnaire data gets paired with the collected medical record history that is maintained in the Registry.

Interventions

OTHERBlood Pressure Measurement

Undergo blood pressure measurement

OTHERQuestionnaire Administration

Complete questionnaires

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aims 1 and 2: A diagnosis of MTC * Aims 1 and 2: A registrant in the Medullary Thyroid Cancer Registry (MTCR). Patients of all disease phases will be eligible for enrollment * Aim 3: A diagnosis of advanced phase (red or gray) MTC as determined by clinical team * Aim 3: A current registrant in the MTCR

Design outcomes

Primary

MeasureTime frameDescription
Natural history of medullary thyroid cancer (MTC)Up to 4 yearsWill describe the natural history of MTC using comprehensive battery of demographic, clinical, pathologic, and genotypic variables collected in existing multi-institutional patient registry.
Patients' experience with the different phases of MTCUp to 4 yearsWill characterize patients' experience with the different phases of MTC through a systematic evaluation of patient-reported outcomes (PROs).
Association of selected biometric and patient-reported outcomesUp to 4 yearsWill evaluate the association of selected biometric and patient-reported outcomes on adherence, change, and discontinuation of approved targeted therapies and drugs being tested within clinical trial.

Countries

United States

Contacts

CONTACTElizabeth G Grubbs
eggrubbs@mdanderson.org713-792-6940
PRINCIPAL_INVESTIGATORElizabeth G Grubbs

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026